心脏分子影像的未来
该综述指出,PET与SPECT分子影像在临床心脏病学与研究中应用广泛,并正经历技术与医学进展带来的快速变化,对诊断、治疗计划与患者照护产生直接影响。综述讨论了已确立放射性药物的新兴临床用途,并重点介绍炎症与浸润性心肌病变、心脏代谢、血管与瓣膜疾病、神经激素失调等领域的分子影像进展,以及人工智能与诊疗一体化等变革性技术进展。
要点
- PET与SPECT分子影像在临床心脏病学与研究中应用广泛,并持续快速变化。
- 技术进展对诊断、治疗计划与患者照护产生直接影响,并为基础与转化研究提供新工具。
- 综述涵盖炎症与浸润性心肌病变、心脏代谢、血管与瓣膜疾病、神经激素失调及人工智能与诊疗一体化。
核心结论
- 综述强调,向混合PET系统转变并整合先进计算工具,伴随机制特异性靶向放射性药物的发展,旨在解决心脏影像长期存在的局限。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- 综述讨论了已确立放射性药物仍在新兴的临床用途,并重点介绍新的显像探针、应用、影像技术与仪器。
- 分子影像进展涵盖炎症与浸润性心肌病变、心脏代谢、血管与瓣膜疾病、神经激素失调。
- 变革性技术进展包括人工智能的兴起与心血管疾病诊疗一体化方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) serves numerous applications in clinical cardiology and research. Similar to other medical imaging technologies, this area has undergone and continues to experience rapid changes resulting from technological and medical advances. These have immediate impacts on diagnosis, treatment planning, and patient care, as well as supplying innovative tools for fundamental and translational research. A broad shift toward hybrid PET systems and incorporation of advanced computational tools has been accompanied by mechanism-specific, targeted radiopharmaceuticals that seek to address long-standing limitations in cardiac imaging. While this review addresses some of the still-emerging clinical uses of established radiopharmaceuticals, it too highlights newer imaging probes, applications, and imaging techniques and instrumentation on the horizon. We highlight molecular imaging advances in inflammatory and infiltrative myocardial conditions, heart metabolism, vascular and valvular diseases, neurohormonal dysregulation, and transformational technical advances such as the rise of artificial intelligence and theranostic approaches to cardiovascular disease.
引用
- Farber G, Boczar KE, Wiefels CC, et al. The Future of Cardiac Molecular Imaging. Semin Nucl Med. 2020. PMID: 32540033. doi:10.1053/j.semnuclmed.2020.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。